5,6,7,8-四氢喹唑啉-2,4-二胺 | 1899-40-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 5,6,7,8-四氢喹唑啉-2,4-二胺
• 英文名称: 2,4-Diamino-5,6,7,8-tetrahydro-chinazolin
• 英文别名: 5,6,7,8-Tetrahydroquinazoline-2,4-diamine
• CAS: 1899-40-7
• 化学式: C₈H₁₂N₄
• mdl: MFCD00111355
• 分子量: 164.21
• InChiKey: ILYYGQJVLQUTAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  77.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-amino-2-methylsulfinyl-5,6,7,8-tetrahydroquinazoline 在 氨 作用下， 以 乙醇 、 水 为溶剂， 反应 7.0h， 以36%的产率得到5,6,7,8-四氢喹唑啉-2,4-二胺
  参考文献：
  名称：

  Sekiya, Tetsuo; Hiranuma, Hidetoshi; Uchide, Masayuki, Chemical and pharmaceutical bulletin, 1981, vol. 29, # 4, p. 948 - 954

  摘要：

  DOI：

文献信息

• POLYMER FILM, RETARDATION FILM, POLARIZING PLATE, LIQUID CRYSTAL DISPLAY, AND COMPOUND
  申请人：FUJIFILM Corporation

  公开号：US20160159750A1

  公开（公告）日：2016-06-09

  Provided is a polymer film containing at least one of a compound represented by formula (1) of hydrates, solvates, or salts thereof. Y is a methine group or nitrogen atom. Q a , Q b , and Q c are a single bond or a divalent linking group. R a , R b , and R c , are hydrogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, cyano group, halogen group, or heterocyclic group. X 2 is a single bond or a divalent linking group. X 1 is a single bond or a predetermined divalent linking group. R 1 and R 2 are a hydrogen atom, alkyl group, alkenyl group, alkynyl group, aryl group, or heterocyclic group Formula (1)

  提供的是一种聚合物薄膜，其中至少包含一种由式（1）表示的化合物的水合物、溶剂合物或盐类。Y是一个亚甲基基团或氮原子。Qa、Qb和Qc是单键或二价连接基团。Ra、Rb和Rc是氢原子、烷基基团、烯基基团、炔基基团、芳基、氰基、卤素基或杂环基。X2是单键或二价连接基团。X1是单键或预定的二价连接基团。R1和R2是氢原子、烷基基团、烯基基团、炔基基团、芳基或杂环基。Formula (1)
• Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof
  申请人：Sekiguchi Yoshinori

  公开号：US20050197350A1

  公开（公告）日：2005-09-08

  The present invention relates to novel compounds of the Formula (I): which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.

  本发明涉及一种新的化合物，其化学式为(I)，该化合物作为MCH受体拮抗剂。这些组合物在制药组合物中的应用包括预防或治疗改善记忆功能、睡眠和觉醒、焦虑、抑郁、情绪障碍、癫痫、肥胖症、糖尿病、食欲和进食障碍、心血管疾病、高血压、血脂异常、心肌梗死、暴食症包括贪食症、厌食症、精神障碍包括躁郁症、精神分裂症、谵妄、痴呆、压力、认知障碍、注意力缺陷障碍、物质滥用障碍和运动障碍包括帕金森病、癫痫和成瘾等。
• PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Bhattacharya Kumar Samit

  公开号：US20080234303A1

  公开（公告）日：2008-09-25

  The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R 1 , R 2 , R 13 , A, K, M, L 1 , L 2 , X, Y 1 , Y 2 , Q, salt thereof, wherein R 1 , R 2 , R 13 , A, K, L 1 , L 2 , W, X, Z 1 , Z 2 , Y 1 , Y 2 , Z 1 , Z 2 , M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本发明涉及式1的化合物或其药学上可接受的盐，其中Ar是式的基团，而R1、R2、R13、A、K、M、L1、L2、X、Y1、Y2、Q、其盐、R1、R2、R13、A、K、L1、L2、W、X、Z1、Z2、Y1、Y2、Z1、Z2、M、Q、W、X、m、p和q的定义如本文所述。这些新型嘧啶衍生物在哺乳动物中治疗异常细胞增长，如癌症方面具有用途。本发明还涉及使用这些化合物在哺乳动物，特别是人类中治疗异常细胞增长的方法，以及含有这些化合物的制药组合物。
• 5,6-Alkylenepyrimidine derivatives, processes for preparing the same and pharmaceutical compositions
  申请人：Mitsubishi Yuka Pharmaceutical Co., Ltd.

  公开号：EP0022481A1

  公开（公告）日：1981-01-21

  There are provided novel compounds, i.e., a 2-piperazino-4-substituted-5,6-alkylenepyrimidine derivative represented by the formula: wherein Y, Z and n are defined in the specification and claims, and a pharmaceutically acceptable acid addition salt thereof. The compounds and pharmaceutical compositions of the present invention show an antihypertensive effect, an anti-inflammatory effect, a blood sugar level lowering effect, a blood platelet aggregation suppressive effect, an anorexigenic action and a Serotonin effect. Further, there are provided herein processes for preparing the above compounds.

  本发明提供了新型化合物，即由以下式子表示的 2-哌嗪基-4-取代-5,6-烯基嘧啶衍生物： 其中 Y、Z 和 n 在说明书和权利要求书中定义，以及其药学上可接受的酸加成盐。 本发明的化合物和药物组合物具有抗高血压作用、抗炎作用、降血糖作用、血小板聚集抑制作用、厌食作用和血清素作用。 此外，本文还提供了制备上述化合物的工艺。
• 707. The preparation of enol ethers from certain β-keto-nitriles
  作者：B. H. Chase、James Walker

  DOI：10.1039/jr9530003518

  日期：——